AstraZeneca receives positive high level results from Phase III I CAN trial.
Drugmaker AstraZeneca said on Tuesday that high‑level results from an interim analysis of its Phase III I CAN trial showed Ultomiris had met its primary endpoint, delivering a statistically significant and meaningful reduction in proteinuria in adults with IgA nephropathy at risk of disease progression.
Source: Sharecast
AstraZeneca said the main efficacy measure - changes in estimated glomerular filtration rates — would be assessed at week 106.
IgA nephropathy is a rare inflammatory kidney condition that can lead to chronic and ultimately end‑stage disease. The FTSE 100-listed company highlighted that more than 560,000 people were diagnosed with the condition across the US, EU5 and Japan - with over 60% eligible for treatment.
AstraZeneca also stated it would seek accelerated approval in key markets and that it will present the trial's results at a forthcoming medical meeting.
As of 0845 BST, AstraZeneca shares were down 1.15% at 14,780p.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
